Caris Life Sciences Raises 2025 Revenue Guidance After Strong Q3 Results

November 06, 2025
Caris Life Sciences reported third-quarter 2025 revenue of $216.8 million, up 113% year-over-year, and raised its full-year revenue guidance to $720–$730 million.

Caris Life Sciences reported third-quarter 2025 revenue of $216.8 million, a 113% increase from the same period last year, announced in a press release. The company attributed the growth to strong performance in its molecular profiling services.

Caris completed 50,763 clinical therapy selection cases during the quarter, marking an 18.2% increase year-over-year. Gross margin improved to 68.0%, representing a 2,432 basis point increase from the prior year period.

The company reported a net income of $24.3 million and positive adjusted EBITDA of $51.2 million. Operating activities generated $62.4 million in net cash flow, with free cash flow reaching $55.3 million.

Based on its performance, Caris raised its full-year 2025 revenue guidance to a range of $720 million to $730 million, representing expected growth of 75% to 77% compared to 2024.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

11/06
Geeks360 Launches AI Platform to Integrate Marketing and Operations for Healthcare Firms
11/06
Fosun Highlights Global Innovation and AI Initiatives at Sustainability Leaders Conference
11/06
Healthcare Triangle Signs LOI to Acquire Teyame.AI for AI-Powered Patient Engagement
11/06
Bain & Company and KLAS Research Report Finds Healthcare AI Focus Shifting to ROI and Workflow Efficiency
11/06
Carta Healthcare Named to CB Insights 2025 Digital Health 50

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like